PHARAMACOVIGILANCE EUROPE CONGRESS

3rd Annual International Conference & Exhibition in Pharmacovigilance, Regulatory Affairs and Risk Management

24th - 25th May 2017, London, UK

www.pveurope.com

info@gravitonevents.org

WELCOME

Dear Members,

We welcome you to attend the 3rd Annual International Conference & Exhibition - Pharmacovigilance Europe 2017 during May 24-25, 2017, London, UK.

Our agendas are tailor-made to precisely suit the industry profile of our attendees. After a comprehensive research study, we categorize the end user giving exclusive opportunities relevant to their business needs and requirements. Moreover, our finest speakers share the same industry background as our delegates. They hold the distinguished position of senior-level decision makers and influential leaders in their field.

Join us for brainstorming sessions filled with innovative ideas and share tete a tete moments with the experts for exclusive advice. Our Networking expertise will ensure with their innovation products/services.

Regards,

Pharmacovigilance Europe 2017 Committee

KEY FEATURES

A Global Event in Pharmacovigilance

Ensuring Pharmacovigilance for Global Public Health

20+ Expert Speakers from around the world

100's Pharma/ Biotech Professionals from over 50 countries

Bringing together the key decision makers under one roof

Over 10 hours of dedicated Networking and Interactive sessions

ABOUT

PHARMACOVIGILANCE EUROPE 2017

On the road to striving towards globalizing and strengthening pharmacovigilance,the Pharmacovigilance Europe 2017 conference is being held as a platform to share experiences and knowledge on the many concerns and advancements in the field. Together with likeminded individuals having the conviction to spread awareness, we shall hope to gain insights on public safety and risk management, focusing mainly on drugs, biologics and medical devices and the future of PV in the globalization era.

The extensive group of experts at the conference will discuss on advancements and trends in EU legislation, operational challenges of changes propounded, implementing global risk management plans, impact of IT and social media on PV and harmonization of different regulatory bodies.

Witnessing the success of Pharmacovigilance Europe 2016 which witnessed more than 70 companies, we are inspired to make this year's conference a larger gathering of people with keen intentions to better the sustenance of drugs and improve their impact on people through strong pharmacovigilance. we welcome you to Pharmacovigilance Europe 2017 for networking and knowledge sharing.

TARGET INDUSTRY

KEY THEMES

- Review of the new EU legislation on pharmacovigilance
- Good Pharmacovigilance and Clinical Practice
- Signal Management - revised GVP guidance
- Current Regulatory Guidelines employed in Pharmacovigilance in Europe and USA
- EU revised and new guidelines on biological drugs
- Managing pharmacovigilance compliance locally: perspectives from a local affiliate
- Digital media: websites and social media and their impact on pharmacovigilance
- Medical Literature Monitoring (MLM) and PSUR repository, PASS, DSUR
- Finding new methods to promote harmonization of regulatory framework- developed and emerging marketsPharmacovigilance Audit and Inspections
- Post-Marketing Authorisation Studies in Drug Risk Surveillance
- How will Brexit affect Pharmacovigilance at present and in the future?
- Role of Biologics in PV
- Patient Support Program

WHO WILL YOU MEET?

Vps,Directors,Heads,Managers, Scientific Advisors , Consultatns ,Research Scholars and professionals with intermediate to advance knowledge and experience in the following:

- ✓ Pharmacovigilance
- ✓ Clinical Trials & CRO's
- ✓ Pharma Recuritment
- ✓ Drug safety
- ✓ Pharmacoepidemiology
- ✓ Clinical Pharmacology
- ✓ Clinical Safety
- ✓ Clinical research & safety
- ✓ Information technology
- ✓ Medical Information
- ✓ Health Outcomes
- ✓ Sales and Marketing
- ✓ Contract Manufacturing
- ✓ Drug Research & Development
- ✓ Information and Clinical Data Management
- ✓ Data analysis

WHO ATTENDS

COMPANY TYPE



Pharma & Biotech
Regulators
Consultancy
Technology Provider
CRO

JOB FUNCTION



Vice President
Director
Global Head
Manager

OUR FIRST ROUND OF EXPERT SPEAKERS

Dr.Heike Schoepper
Head Global Drug Safety Regions,
Merck Serono

Dr.Jackie Roberts
Executive Director – Regulatory, PHV and Medical,
Actavis

Dr.Mircea Ciuca
Head of Medical and Clinical Drug Safety
Vifor Pharma Switzerland

Dr.Emanuel Lohrmann
Lead Safety Physician
Boehringer Ingelheim

Dr.Bert P Van Leeuwen
Global Pharmacovigilance Department
Astellas Pharma

Dr.Shelley Gandhi
Director Pharmacovigilance and
Drug afety ,NDA Group AB, UK

Dr.Tatjana Ajhler Duretek
Head Of Medical Affairs and
Pharmacovigilance,
Belupo Pharmaceuticals

OUR FIRST ROUND OF EXPERT SPEAKERS

Dr.Anita Rakic
LQPPV, Global Drug Safety-Regions,Global Medical Affairs and Drug Safety, Global R&D
Merck Biopharma

Dr Giovanni Furlan
Helsinn Birex Pharmaceuticals
Ireland

Ashok Srivastava
Medical Oncologist & Chief Medical Officer
ARKAYA PHARMA, USA

Vaska Tone
President & CEO
LaVaPharm Consulting, USA

DAY 1 AGENDA

08:30	Registration & Refreshments
09:30 - 9:45	Chairperson's opening remarks **Shelley Gandhi Director, NDA**
09:45 - 10:30	Monitoring of Safety Data to Management of the Benefit-Risk Profile - Do we have a good understanding of Risks in the context of benefit? - Benefit-Risk: Does one size fit all? - Can we manage the Benefit-Risk profile of a product? **Dr Heike Schoepper, Head Global Drug Safety Regions, Merck Serono, Germany**
10:30 - 11:00	Power Networking – An Ice Breaker Session
11:00 - 11:30	Morning Coffee/Tea & Networking
	RISK MANAGEMENT
11:30 - 12:00	Implementation of additional risk management measures **Dr Emanuel Lohrmann Lead Safety Physician Boehringer Ingelheim, Germany**

DAY 1 AGENDA

12:00 – 12:30	Pharmacovigilance (PV) outsourcing standard Can Pharmacovigilance learn from the oil and gas industry? **Bert P van Leeuwen, MD Global Pharmacovigilance Astellas Pharma, Netherlands**
12:30 – 13:30	Networking luncheon
13:30 – 14:00	**Proposed Good PV outsourcing standards** - Failure is a likely to occur if cost saving is the only goal of the pharmaceutical company outsourcing its pharmacovigilance activities - Clients and service providers should understand and openly discuss each other's needs, avoiding unrealistic expectations - Clients should always have in house a pharmacovigilance expert to provide constant feedback to the service provider **Dr. Giovanni Furlan** **EU QPPV Helsinn Birex Pharmaceuticals Ireland**
14:00 – 15:00	**Panel Discussion:**
14:30 – 15:00	**PRAC Strategy on measuring the impact of Pharmacovigilance activities**
15:00 - 15:30	Afternoon Tea/Coffee
15:30 - 16:00	TBC Vaska Tone President & CEO LaVaPharm Consulting, USA
16:00 - 16:30	Sponsor Session
16:30 - 17:00	Sponsor Session
17:00	Chairperson's closing remarks
17:10 - 18:30	Networking Drinks Reception

DAY 2 AGENDA

08:30 - 09:30	Registration & Refreshments
09:30 -09:45	Chairperson's opening remarks **Shelley Gandhi, Director, NDA**
09:45 - 10:30	Opening Keynote Address
	SIGNAL MANAGEMENT
10:30 - 11:00	Signal Management - revised GVP guidance Dr Mircea Ciuca, Head of Medical and Clinical Drug Safety, Vifor Pharma, Switzerland
11:00 - 11:30	**Morning Coffee/Tea & Networking**
	CHALLENGES & OPPORTUNITIES
11:30 - 12:00	GVPs, challenges to the generic industry and how to overcome them - Is there difference in interpretation of GVP modules between generic and - Benefit-risk assessment for great number of drugs - What does signal management mean for generic industry - Challenges of risk minimization measures and safety communication for generic drugs **Dr.Tatjana Ajhler Duretek ,Head Of Medical Affairs and Pharmacovigilance,Belupo Pharmaceuticals**
12:00 – 12:30	**Managing Pharmacovigilance Compliance locally: perspectives from a local affiliate** - Change and Ensuring compliance - Organizational structures – what is best done locally vs globally? - Risks and benefits of a local PV function **Dr Jackie Roberts, Director of Regulatory, Pharmacovigilance and Medical, Actavis**
12:30 - 13:30	**Networking luncheon**

DAY 2 AGENDA

13:30 – 14:30	Panel Discussion - Patient Support Programme
14:30 - 15:00	Post-Marketing Authorisation Studies in Drug Risk Surveillance **'PASS studies: Options and practicalities'** - Regulatory aspects - Safety issues, designs and data sources - Risk minimisation evaluation studies - Data Integration **Dr Nawab Qizilbash OXON Epidemiology**
15:00 - 15:30	**PV Audit and Inspections** - Internal audit programmes – expectations for scheduling, conduct and follow-up - Regulatory inspections – thoughts on maintaining inspection-readiness, and preparing staff and documentation for inspection **Dr Miranda Dollen, Vice President, MAPI Group, UK**
15:30 - 16:00	Afternoon Tea/Coffee
16:00 - 16:30	Good Pharmacovigilance and Clinical Practice"; "Challenges in Drug safety in Cancer Patients and Treatment **Ashok Srivastava** **Medical Oncologist & Chief Medical Officer,** **ARKAYA PHARMA, USA**
16:30 - 17:00	Pharmacovigilance legislation in the non-EU Balkan countries **Dr Anita Rakic, Global Medical R&D, Merck Biopharma.**
17:00 - 17:10	Chairperson's closing remarks and end of conference

PAST ATTENDEES TESTIMONIAL

IPSEN
Innovation for patient care

Graviton did an excellent job by bringing so many busy Pharmacovigilance professionals together in a room who stayed throughout the day is a testimony to how interesting the event was, also it has been very educational and informative

Senior Vice President,
Global Pharmacovigilance,
Ipsen BioPharma

Wolters Kluwer

Attending an event like this makes me complete more than 50 client meetings in one place and a short span of time, rather than going out to meet clients across the country

Exhibitor,
Wolters Kluwer

MERCK

PV Europe 2016 was an excellent platform for communication

Head of Global
Drug Safety, Merck

Explore

LONDON

UNITED KINGDOM

London, the capital city of England set on the river Thames,
is a 21st Century city with histories stretching back to Roman times.
At its centre stand the imposing houses of parliament, the iconic “Big Ben” Clock Tower and Westminster Abbey, site of British Monarch Coronations. Across the Thames, the London Eye observation wheel provides panoramic views of the South Bank cultural complex, and the entire city.

London is a leading global city with strengths in the arts, commerce, education, entertainment, fashion, finance, health care, media, professional services, research and development, tourism & transports all contributing to its prominence. It is one of the World’s Leading Financial Centers. London has a diverse range of peoples and cultures, and more than 300 languages are spoken within Greater London.

London is a world cultural capital is the world's most-visited city as measured by international arrivals London is the world's leading investment destination and best place for International Brand Promotion and Conferences.

OUR SPONSORS & SUPPORTERS

Supported By

TMC PHARMA

iptechex
Bringing ideas to market

UK Pharmacogenetics & Stratified Medicine Network

ASPHALION
Knowledge from Experience

PharmaVOICE

pharmaphorum
bringing healthcare together

Wolters Kluwer

ROYAL SOCIETY OF CHEMISTRY

CONFERENCE locate.com

AB-Cube

Eventbrite

Radian Scientific L.i.m.i.t.e.d

SelectScience
The Fastest Way to Expert Opinion

WORLD SCIENCE & KNOWLEDGE FORUM
CONNECT • COMMUNICATE • COLLABORATE

HORIZON Consultancy

rbw consulting

Cmed

PHARSOLUTION

EXTEDO
eRegulatory Affairs

PHARMACOVIGILANCE EUROPE CONGRESS

Important Dates:

Abstract Submission last date: 26th February 2017

Super Early Bird offer ends 26th February 2017

Early Bird Offer ends 30th March 2017

Conference Venue

Hilton London Olympia,
380 Kensington High St,
Kensington,London W14 8NL

CONTACT US:

Conference Secretariat

GRAVITON INTERNATIONAL

Email: pharmacovigilance@gravitonevents.org
UK / Tel: +44(0)2033718514
Website : www.pveurope.com